Monitoring of mycophenolate mofetil in orthotopic heart transplant recipients—a systematic review☆
published online 03 April 2009.
Abstract
Background
Recent attention has focused on individualizing mycophenolate mofetil therapy via monitoring of mycophenolic acid (MPA) levels to overcome interpatient variability in MPA exposure when standard doses are administered. To our knowledge, no systematic review of the pharmacokinetic data in orthotopic heart transplant recipients has been published to date.
Objective
The study aimed to systematically review published studies on the MPA target concentration that is effective at preventing rejection in cardiac transplant patients.
Methodology
A search of MEDLINE (January 1996 to July 2008) and EMBASE (January 1980 to July 2008) was conducted for articles describing the relationship between rejection and MPA concentration.
Results
The literature search yielded 7 citations for inclusion: 1 prospective, randomized controlled study (level I); 2 prospective, nonrandomized controlled studies (level II-1); 1 well-designed cohort study (level II-2); 2 retrospective cohort studies (level II-3); and 1 case report (level III).
Conclusions
The relationship between MPA levels and rejection cannot be clearly defined based on available evidence. Preliminary evidence suggests limited sampling strategies may be a better predictor of rejection than a single-time point model. Further studies must be conducted on the relationship between the MPA area under the curve, the risk of rejection, and adverse effects to appreciate the value of such strategies.
aDepartment of Medicine, University of Alberta, Edmonton, AB, Canada T6G 2B7
bDivision of Cardiology, Department of Medicine, University of Alberta, Edmonton AB, Canada T6G 2B7
Corresponding author. Suite 2C2, Walter Mackenzie Health Sciences Centre, Edmonton, AB, Canada T6G 2B7. Tel.: +1 780 407 1590; fax: +1 780 407 1496.
☆ The article has neither been submitted nor is it under consideration for publication elsewhere.
ABSTRACT